Degenerative cervical myelopathy (DCM) is a chronic progressive disease of the cervical spinal cord. Osteoarthritic degeneration (spondylosis, facet hypertrophy, and degenerative disc disease), ligament changes (ossification of the posterior longitudinal ligament, hypertrophy of the ligamentum flavum) may lead to the spinal cord compression and result in neurological deficits. It is manifested as clumsy hands syndrome, gait impairment, and bladder problems. The latest clinical guidelines recommend surgery for patients with moderate and severe DCM. For patients with mild DCM (or non-myelopathic patients with radiculopathy), the guidelines suggest that either surgery or a supervised trial of structured rehabilitation. The nonoperative treatment with serial clinical follow-up should be reserved for asymptomatic patients with imaging evidence of cervical spinal cord compression.

Degenerativní cervikální myelopatie (DCM) je chronické, progresivní onemocnění krční míchy. Degenerativní procesy (spondylóza, hypertrofie facetových kloubů, výhřezy plotének) včetně postižení vazů (osifikace zadního podélného vazu, hypertrofie ligamentum flavum) vedou k míšní kompresi a rozvoji možného neurologického deficitu. Ten se projevuje zejména syndromem neobratných rukou, zhoršením chůze a sfinkterovou insuficiencí. Podle současných doporučení by měli být nemocní se střední a těžkou formou DCM léčeni operativně. U pacientů s lehkou formou DCM a pacientů bez klinických známek myelopatie, avšak s projevy radikulopatie, by měla být navržena buď operační léčba, či cílená rehabilitace. Jedinci s průkazem významné míšní komprese (avšak bez klinických známek myelopatie či radikulopatie) by měli být pravidelně klinicky sledováni.

• MeSH
• diagnostické techniky neurologické MeSH
• klinický obraz nemoci MeSH
• komprese míchy diagnóza   etiologie   patologie   terapie   MeSH
• krční obratle patologie   MeSH
• lidé MeSH
• nemoci míchy * diagnóza   patologie   terapie   MeSH
• neurologické vyšetření metody   MeSH
• spinální stenóza diagnóza   etiologie   terapie   MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• přehledy MeSH

Lumbar spinal stenosis (LSS) is a clinical-radiological syndrome, a recent definition covers both the clinical manifestation and the anatomic abnormalities (narrowing of the spinal canal). The symptoms and signs usually begin in the 6th decade. The LSS contributes to impaired mobility in older age, but it is often underdiagnosed. Clinical manifestation includes neurogenic claudication, radicular syndrome, cauda equina syndrome, and low back pain is often present. Diagnosis and therapy of patients with LSS are multidisciplinary issues. This review focuses on updating knowledge of LSS clinical manifestation, diagnosis, and therapeutic strategy.

Lumbální spinální stenóza (LSS) je klinicko­‐radiologický syndrom, nejnovější definice zohledňuje klinickou manifestaci i anatomické změny (zúžení páteřního kanálu). Převažujícím věkem začátku potíží je šestá dekáda. Onemocnění bývá poddiagnostikováno, přičemž přispívá k omezení mobility starších pacientů. Může se manifestovat neurogenními klaudikacemi, radikulárním syndromem či syndromem kaudy equiny, často se vyskytují i bolesti dolní části zad. Diagnostika a terapie pacientů s LSS je multidisciplinární záležitost. V tomto přehledu jsou shrnuty recentní poznatky týkající se klinické manifestace, diagnostiky a strategie léčby u pacientů s LSS.

• MeSH
• bederní obratle patologie   MeSH
• diagnostické zobrazování metody   MeSH
• komprese míchy * diagnóza   etiologie   patologie   terapie   MeSH
• konzervativní terapie MeSH
• lidé MeSH
• neurologické vyšetření metody   MeSH
• spinální stenóza diagnóza   terapie   MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• práce podpořená grantem MeSH

Patients with lumbar spinal stenosis may experience symptoms such as back pain, nerve root irritation and neurogenic claudication. Although studies have shown that differences between non-surgical and surgical treatments are not significant, positive effects such as early pain relief, associated functional improvement and higher quality of life, may be expected after surgery in patients with severe lumbar stenosis. Surgical treatment consists of decompression of nerve structures. Additional stabilization is considered depending on the degree of decompression and accompanying instability. Recently introduced techniques of minimally invasive surgery bring promising surgical results and their further development can be expected in the near future. Thus, even better therapeutic effects may be expected with an approach aimed at understanding the pathophysiology, taking into account morphology and knowledge of predictors of treatment methods for lumbar spinal stenosis.

Pacienti s bederní spinální stenózou mohou vykazovat příznaky, jakými jsou bolest zad, kořenové iritace a neurogenní klaudikace. Přestože podle dosavadních studií nejsou rozdíly mezi konzervativním a chirurgickým způsobem léčby jednoznačné, lze po operaci pacienta s těžkou bederní stenózou očekávat pozitivní účinky, jako je časný ústup bolesti, související zlepšení funkčnosti a zvýšení kvality života. Chirurgická léčba spočívá v dekompresi nervových struktur. Přídatnou stabilizaci zvažujeme v závislosti na stupni dekomprese a doprovodné nestabilitě. Recentně zaváděné techniky minimálně invazivní chirurgie přinášejí slibné výsledky a v blízkém horizontu lze očekávat jejich další rozvoj. Optimální výsledek léčby lze očekávat při obsáhnutí patofyziologie, znalosti morfologie a pochopení prediktorů léčebných metod lumbální stenózy.

• MeSH
• bederní obratle patologie   MeSH
• chirurgická dekomprese metody   MeSH
• diagnostické zobrazování metody   MeSH
• fúze páteře MeSH
• komprese míchy chirurgie   patologie   MeSH
• lidé MeSH
• spinální stenóza * chirurgie   diagnóza   patologie   MeSH
• výztuhy MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• přehledy MeSH

Degenerative cervical myelopathy (DCM) is a consequence of a degenerative disease of the cervical spine leading to stenosis of the cervical canal and eventually to compression of the cervical spinal cord. DCM involves about 2% of the population and despite all accessible therapeutic options it could lead to a significant disability. Signs of cervical spinal cord compression detected with magnetic resonance imaging (MRI), however, end up in clinically symptomatic myelopathy in a smaller part of individuals with compression, while the rest remains without clinical symptoms and signs of cervical myelopathy - so called non-myelopathic degenerative cervical cord compression (NMDCC). The prevalence of NMDCC increases with age and in a population older than 60 years of age NMDCC involves at least one third of individuals. The review recapitulates current knowledge on a natural course of NMDCC, predictors of progression into DCM stage and a role of innovative quantitative MRI techniques in both research and practical management of degenerative cervical compression.

Degenerativní cervikální myelopatie (DCM) je následkem degenerativního onemocnění krční páteře vedoucího ke stenóze spinálního kanálu a následné míšní kompresi. DCM postihuje přibližně 2 % populace a vede i při současných metodách léčby k významné disabilitě. Známky komprese krční míchy zjištěné pomocí magnetické rezonance (MR) však vedou k manifestní myelopatii pouze u menší části nemocných, zatímco u většiny zůstává komprese bez klinických známek myelopatie - tzv. nemyelopatická komprese krční míchy (NMDCC). Prevalence NMDCC narůstá s věkem a v populaci nad 60 let věku postihuje minimálně 1/3 jedinců. Přehled přináší rekapitulaci dosavadních poznatků o přirozeném průběhu NMDCC, prediktorech progrese do stadia DCM a úloze inovativních kvantitativních MR technik ve výzkumu a praktickém managementu degenerativní míšní komprese.

• MeSH
• komprese míchy * diagnóza   etiologie   patologie   MeSH
• krční obratle patologie   MeSH
• lidé MeSH
• magnetická rezonanční tomografie metody   MeSH
• nemoci míchy diagnóza   etiologie   patologie   MeSH
• spinální stenóza etiologie   MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• práce podpořená grantem MeSH

Degenerative cervical myelopathy (DCM) is a severe consequence of degenerative cervical spinal cord (CSC) compression. The non-myelopathic stage of compression (NMDC) is highly prevalent and often progresses to disabling DCM. This study aims to disclose markers of progressive neurochemical alterations in NMDC and DCM by utilizing an approach based on state-of-the-art proton magnetic resonance spectroscopy (1H-MRS). Proton-MRS data were prospectively acquired from 73 participants with CSC compression and 47 healthy controls (HCs). The MRS voxel was centered at the C2 level. Compression-affected participants were clinically categorized as NMDC and DCM, radiologically as mild (MC) or severe (SC) compression. CSC volumes and neurochemical concentrations were compared between cohorts (HC vs. NMDC vs. DCM and HC vs. MC vs. SC) with general linear models adjusted for age and height (pFWE < 0.05) and correlated to stenosis severity, electrophysiology, and myelopathy symptoms (p < 0.05). Whereas the ratio of total creatine (tCr) to total N-acetylaspartate (tNAA) increased in NMDC (+11%) and in DCM (+26%) and SC (+21%), myo-inositol/tNAA, glutamate + glutamine/tNAA, and volumes changed only in DCM (+20%, +73%, and -14%) and SC (+12%, +46%, and -8%, respectively) relative to HCs. Both tCr/tNAA and myo-inositol/tNAA correlated with compression severity and volume (-0.376 < r < -0.259). Myo-inositol/tNAA correlated with myelopathy symptoms (r = -0.670), whereas CSC volume did not. Short-echo 1H-MRS provided neurochemical signatures of CSC impairment that reflected compression severity and clinical significance. Whereas volumetry only reflected clinically manifest myelopathy (DCM), MRS detected neurochemical changes already before the onset of myelopathy symptoms.

• MeSH
• dospělí MeSH
• inositol metabolismus   MeSH
• komprese míchy metabolismus   patologie   MeSH
• krční mícha * MeSH
• krční obratle MeSH
• kreatin metabolismus   MeSH
• kyselina asparagová analogy a deriváty   metabolismus   MeSH
• kyselina glutamová metabolismus   MeSH
• lidé středního věku MeSH
• lidé MeSH
• magnetická rezonanční spektroskopie * MeSH
• senioři MeSH
• senzitivita a specificita MeSH
• studie případů a kontrol MeSH
• stupeň závažnosti nemoci MeSH
• Check Tag
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH
• Research Support, N.I.H., Extramural MeSH

Diffusion magnetic resonance imaging (dMRI) proved promising in patients with non-myelopathic degenerative cervical cord compression (NMDCCC), i.e., without clinically manifested myelopathy. Aim of the study is to present a fast multi-shell HARDI-ZOOMit dMRI protocol and validate its usability to detect microstructural myelopathy in NMDCCC patients. In 7 young healthy volunteers, 13 age-comparable healthy controls, 18 patients with mild NMDCCC and 15 patients with severe NMDCCC, the protocol provided higher signal-to-noise ratio, enhanced visualization of white/gray matter structures in microstructural maps, improved dMRI metric reproducibility, preserved sensitivity (SE = 87.88%) and increased specificity (SP = 92.31%) of control-patient group differences when compared to DTI-RESOLVE protocol (SE = 87.88%, SP = 76.92%). Of the 56 tested microstructural parameters, HARDI-ZOOMit yielded significant patient-control differences in 19 parameters, whereas in DTI-RESOLVE data, differences were observed in 10 parameters, with mostly lower robustness. Novel marker the white-gray matter diffusivity gradient demonstrated the highest separation. HARDI-ZOOMit protocol detected larger number of crossing fibers (5-15% of voxels) with physiologically plausible orientations than DTI-RESOLVE protocol (0-8% of voxels). Crossings were detected in areas of dorsal horns and anterior white commissure. HARDI-ZOOMit protocol proved to be a sensitive and practical tool for clinical quantitative spinal cord imaging.

• MeSH
• biomedicínské inženýrství MeSH
• difuzní magnetická rezonance * MeSH
• dospělí MeSH
• komprese míchy diagnostické zobrazování   patologie   MeSH
• krční obratle patologie   MeSH
• lidé středního věku MeSH
• lidé MeSH
• nemoci míchy diagnostické zobrazování   patologie   MeSH
• poměr signál - šum MeSH
• reprodukovatelnost výsledků MeSH
• senzitivita a specificita MeSH
• shluková analýza MeSH
• studie případů a kontrol MeSH
• zobrazování difuzních tenzorů MeSH
• Check Tag
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH
• Research Support, N.I.H., Extramural MeSH

BACKGROUND: Multiple myeloma is characterised by monoclonal paraprotein production and osteolytic lesions, commonly leading to skeletal-related events (spinal cord compression, pathological fracture, or surgery or radiotherapy to affected bone). Denosumab, a monoclonal antibody targeting RANKL, reduces skeletal-related events associated with bone lesions or metastases in patients with advanced solid tumours. This study aimed to assess the efficacy and safety of denosumab compared with zoledronic acid for the prevention of skeletal-related events in patients with newly diagnosed multiple myeloma. METHODS: In this international, double-blind, double-dummy, randomised, active-controlled, phase 3 study, patients in 259 centres and 29 countries aged 18 years or older with symptomatic newly diagnosed multiple myeloma who had at least one documented lytic bone lesion were randomly assigned (1:1; centrally, by interactive voice response system using a fixed stratified permuted block randomisation list with a block size of four) to subcutaneous denosumab 120 mg plus intravenous placebo every 4 weeks or intravenous zoledronic acid 4 mg plus subcutaneous placebo every 4 weeks (both groups also received investigators' choice of first-line antimyeloma therapy). Stratification was by intent to undergo autologous transplantation, antimyeloma therapy, International Staging System stage, previous skeletal-related events, and region. The clinical study team and patients were masked to treatment assignments. The primary endpoint was non-inferiority of denosumab to zoledronic acid with respect to time to first skeletal-related event in the full analysis set (all randomly assigned patients). All safety endpoints were analysed in the safety analysis set, which includes all randomly assigned patients who received at least one dose of active study drug. This study is registered with ClinicalTrials.gov, number NCT01345019. FINDINGS: From May 17, 2012, to March 29, 2016, we enrolled 1718 patients and randomly assigned 859 to each treatment group. The study met the primary endpoint; denosumab was non-inferior to zoledronic acid for time to first skeletal-related event (hazard ratio 0·98, 95% CI 0·85-1·14; pnon-inferiority=0·010). 1702 patients received at least one dose of the investigational drug and were included in the safety analysis (850 patients receiving denosumab and 852 receiving zoledronic acid). The most common grade 3 or worse treatment-emergent adverse events for denosumab and zoledronic acid were neutropenia (126 [15%] vs 125 [15%]), thrombocytopenia (120 [14%] vs 103 [12%]), anaemia (100 [12%] vs 85 [10%]), febrile neutropenia (96 [11%] vs 87 [10%]), and pneumonia (65 [8%] vs 70 [8%]). Renal toxicity was reported in 85 (10%) patients in the denosumab group versus 146 (17%) in the zoledronic acid group; hypocalcaemia adverse events were reported in 144 (17%) versus 106 (12%). Incidence of osteonecrosis of the jaw was not significantly different between the denosumab and zoledronic acid groups (35 [4%] vs 24 [3%]; p=0·147). The most common serious adverse event for both treatment groups was pneumonia (71 [8%] vs 69 [8%]). One patient in the zoledronic acid group died of cardiac arrest that was deemed treatment-related. INTERPRETATION: In patients with newly diagnosed multiple myeloma, denosumab was non-inferior to zoledronic acid for time to skeletal-related events. The results from this study suggest denosumab could be an additional option for the standard of care for patients with multiple myeloma with bone disease. FUNDING: Amgen.

• MeSH
• časové faktory MeSH
• denosumab škodlivé účinky   terapeutické užití   MeSH
• doba přežití bez progrese choroby MeSH
• dvojitá slepá metoda MeSH
• fraktury spontánní etiologie   mortalita   patologie   prevence a kontrola   MeSH
• inhibitory kostní resorpce škodlivé účinky   terapeutické užití   MeSH
• komprese míchy etiologie   mortalita   patologie   prevence a kontrola   MeSH
• kyselina zoledronová škodlivé účinky   terapeutické užití   MeSH
• lidé středního věku MeSH
• lidé MeSH
• mnohočetný myelom komplikace   farmakoterapie   mortalita   patologie   MeSH
• nádory kostí komplikace   mortalita   prevence a kontrola   sekundární   MeSH
• protinádorové látky škodlivé účinky   terapeutické užití   MeSH
• rizikové faktory MeSH
• senioři MeSH
• výsledek terapie MeSH
• Check Tag
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• klinické zkoušky, fáze III MeSH
• multicentrická studie MeSH
• práce podpořená grantem MeSH
• randomizované kontrolované studie MeSH
• srovnávací studie MeSH

BACKGROUND: Bone complications, also known as skeletal-related events (SREs), are common in patients with bone metastases secondary to advanced cancers. OBJECTIVE: To provide a detailed estimate of the health resource utilization (HRU) burden associated with SREs across eight European countries. METHODS: Eligible patients from centers in Austria, the Czech Republic, Finland, Greece, Poland, Portugal, Sweden, and Switzerland with bone metastases or lesions secondary to breast cancer, prostate, or lung cancer or multiple myeloma who had experienced at least one SRE (defined as radiation to bone, long-bone pathologic fracture, other bone pathologic fracture, surgery to bone or spinal cord compression) were entered into this study. HRU data were extracted retrospectively from the patients' charts from 3.5 months before the index SRE until 3 months after the index SRE (defined as an SRE preceded by an SRE-free period of at least 6.5 months). RESULTS: Overall, the mean number of inpatient stays per SRE increased from baseline by approximately 0.5-1.5 stays, with increases in the total duration of inpatient stays of approximately 6-37 days per event. All SREs were associated with substantial increases from baseline in the frequency of procedures and the number of outpatient and day-care visits. CONCLUSIONS: SREs are associated with substantial HRU owing to considerable increases in the number and duration of inpatient stays, and in the number of procedures, outpatient visits, and day-care visits. These data collectively provide a valuable summary of the real-world SRE burden on European healthcare systems.

• MeSH
• délka pobytu statistika a číselné údaje   MeSH
• fraktury kostí patologie   MeSH
• hospitalizace statistika a číselné údaje   MeSH
• komprese míchy patologie   MeSH
• lidé středního věku MeSH
• lidé MeSH
• metastázy nádorů MeSH
• mnohočetný myelom MeSH
• nádory kostí epidemiologie   radioterapie   sekundární   MeSH
• nádory plic MeSH
• nádory prostaty epidemiologie   patologie   MeSH
• nádory prsu epidemiologie   patologie   MeSH
• primární zdravotní péče statistika a číselné údaje   MeSH
• retrospektivní studie MeSH
• senioři nad 80 let MeSH
• senioři MeSH
• Check Tag
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• senioři nad 80 let MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• srovnávací studie MeSH
• Geografické názvy
• Evropa epidemiologie   MeSH

PURPOSE OF THE STUDY: The aim of the study was to measure the sensorimotor brain adaptation activity, shown on functional magnetic resonance images (fMRI), in relation to the degree and extent of spinal cord compression or cervical spondylotic myelopathy (CSM) detected by cervical spine MRI. MATERIAL AND METHODS: Twenty-one patients (average age, 57 years; 9 men and 12 women) with anterior cervical cord compression detected on cervical MRI scans were included. On the images, the degree of spinal canal stenosis, the spinal cord compression based on the antero-posterior diameter of the spinal canal and on transverse areas of the cervical spinal cord and cervical spinal canal, and changes in spinal cord signal intensity were identified. Clinical examination included neurological status, Japanese Orthopaedic Association (JOA) score, Neck Disability Index (NDI) and pain intensity assessment using the Visual Analogue Scale (VAS). Electrophysiological tests involving motor evoked and sensory evoked potential (MEP and SEP) recording were conducted and, using fMRI, brain activity during movement of both arms was measured. Based on the transverse spinal cord area of above or below 70 mm2, the patients were placed into two subgroups. According to changes in spinal cord signal intensity, the patients were included into three subgroups with normal findings, incipient myelopathy and advanced myelopathy, respectively. Surgery was carried out from the anterior approach and involved cervical disc replacement. All examinations were performed again at 6 months after surgery. Pre- and post-operative results were compared within each set of subgroups and statistically evaluated. RESULTS: The average pre-operative values were found to increase post-operatively as follows: from 6.4 mm to 8.9 mm (by 39%) for the antero-posterior diameter of the spinal canal; from 129.3 mm2 to 162.8 mm2 (by 26%) for the transverse area of the spinal canal; from 72.6 mm2 to 87.4 mm2 (by 20%) for the transverse spinal cord area; and from 16.3 to 17.4 for the JOA score. The average NDI decreased from 37.9 to 23.7 and the average VAS fell from 6.4 to 1.5. All patients with the change of spinal cord signal that indicated advanced myelopathy also had relevant pathological findings on MEP/SEP examination and this was statistically significant. There was no significant difference in fMRI scans between the two subgroups established on the basis of transverse spinal cord area measurements. In the patients grouped by a change in spinal cord signals, the pre-operative fMRI showed a significantly higher brain activation volume in the subgroup with advanced myelopathy, as compared with the two other subgroups. Surgery resulted in a moderate reduction of the volume of active brain tissue in all three groups. In the patients with advanced myelopathy evaluated in relation to local changes in brain activation, surgery led to a significant decrease in activation volumes in the ipsilateral primary motor cortex and cerebellar hemisphere. There was also a significant increase in activation of the contralateral supplementary motor cortex. DISCUSSION: It is evident that the brain responds to spinal cord damage by increased activity, but with a certain delay. A slightly altered spinal cord signal intensity, such as in incipient myelopathy, apparently does not result in brain activation. On the other hand, significant changes in signal intensity in advanced myelopathy are related to deterioration of spinal cord function, as shown by MEP and SEP examination results, and an increase in both the volume and intensity of cortical motor activation as a compensation mechanism for myelopathy. CONCLUSIONS Hyperintense spinal cord signals on T2-weighted images correlated with the pathological spinal cord function detected by electrophysiological test in all patients. The transverse spinal cord area (around 70 mm2) showed no significant correlation with either sensory and motor brain adaptations or the results of SEP and MEP testing; therefore, as a criterion for indication to surgery it is of no value. The patients with advanced myelopathy, as detected by spinal cord MRI, had a significantly higher pre-operative cortical motor activation on fMRI than patients with normal findings or those with incipient myelopathy. In addition, the patterns of cortical motor activation altered significantly at 6 months after spinal cord decompression, which was shown by an increase or decrease in activation of the relevant motor cortex areas.

• MeSH
• chirurgická dekomprese MeSH
• komprese míchy patologie   patofyziologie   chirurgie   MeSH
• krční obratle patologie   patofyziologie   chirurgie   MeSH
• lidé středního věku MeSH
• lidé MeSH
• magnetická rezonanční tomografie * MeSH
• motorické evokované potenciály MeSH
• senioři MeSH
• somatosenzorické evokované potenciály MeSH
• spondylóza patologie   patofyziologie   chirurgie   MeSH
• Check Tag
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH

PURPOSE: The aim of this prospective cross-sectional observational comparative study was to determine the prevalence of spondylotic cervical cord compression (SCCC) and symptomatic cervical spondylotic myelopathy (CSM) in patients with symptomatic lumbar spinal stenosis (LSS) in comparison with a general population sample and to seek to identify predictors for the development of CSM. METHODS: A group of 78 patients with LSS (48 men, median age 66 years) was compared with a randomly selected age- and sex-matched group of 78 volunteers (38 men, median age 66 years). We evaluated magnetic resonance imaging findings from the cervical spine and neurological examination. RESULTS: The presence of SCCC was demonstrated in 84.6% of patients with LSS, but also in 57.7% of a sample of volunteers randomly recruited from the general population. Clinically symptomatic CSM was found in 16.7% of LSS patients in comparison with 1.3% of volunteers (p = 0.001). Multivariable logistic regression proposed the Oswestry Disability Index of 43% or more as the only independent predictor of symptomatic CSM in LSS patients (OR 9.41, p = 0.008). CONCLUSIONS: The presence of symptomatic LSS increases the risk of SCCC; the prevalence of SCCC is higher in patients with symptomatic LSS in comparison with the general population, with an evident predominance of more serious types of MRI-detected compression and a clinically symptomatic form (CSM). Symptomatic CSM is more likely in LSS patients with higher disability as assessed by the Oswestry Disability Index.

• MeSH
• bederní obratle patologie   MeSH
• dospělí MeSH
• komprese míchy patologie   MeSH
• lidé středního věku MeSH
• lidé MeSH
• magnetická rezonanční tomografie * MeSH
• neurologické vyšetření MeSH
• posuzování pracovní neschopnosti MeSH
• prospektivní studie MeSH
• průřezové studie MeSH
• senioři nad 80 let MeSH
• senioři MeSH
• spinální stenóza patologie   MeSH
• spondylóza patologie   MeSH
• studie případů a kontrol MeSH
• Check Tag
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• senioři nad 80 let MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• pozorovací studie MeSH
• práce podpořená grantem MeSH